We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

Fund managers haven’t disclosed any holdings of ZNTL yet.

ZNTL Hedge Fund Activity: Q1 2026 in Review

102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.

  • 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
  • Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
  • 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2026.